Cervomed INC Schedule 13G passive stakes

CVI Investments, Inc. and Heights Capital Management, Inc. report a 0.0% beneficial ownership of CervoMed Inc. common stock.

Woodline Partners LP has disclosed beneficial ownership of 5.1% of CervoMed Inc.'s common stock, holding 688,987 shares as of June 30, 2026.

Investment firm Armistice Capital, LLC, along with its managing member Steven Boyd, has reported beneficial ownership of 1,592,863 shares, representing 9.53% of CervoMed Inc.'s common stock.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed a Schedule 13G, indicating a reduction in their beneficial ownership of CervoMed Inc. common stock to below the 5% threshold.

CVI Investments, Inc. and Heights Capital Management, Inc. have filed a Schedule 13G reporting a 5.5% beneficial ownership stake in CervoMed Inc.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed a Schedule 13G, reporting beneficial ownership of 8.0% of CervoMed Inc. common stock as of March 31, 2026.

AWM Investment Company, Inc. reports beneficial ownership of 405,165 warrants in CervoMed Inc., representing 4.2% of the class, as of March 31, 2026.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have reported a combined beneficial ownership of 5.1% in CervoMed Inc's common stock.

RA Capital Management amends its Schedule 13G filing for CervoMed Inc. to correct a clerical error regarding beneficial ownership of shares underlying warrants.

RA Capital Management and its affiliates have fully divested their beneficial ownership in CervoMed Inc., reducing their stake to 0.0%.

AWM Investment Company, Inc. has reported a 9.9% beneficial ownership stake in CervoMed Inc., holding 863,200 shares of common stock as of March 31, 2025.

RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. have jointly filed an amended Schedule 13G, disclosing a 9.9% beneficial ownership stake in CervoMed Inc. as of December 31, 2024.

AWM Investment Company, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.7% of CervoMed Inc.'s common stock, primarily through 405,165 warrants.